Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innova CaptabNSE:INNOVACAP +0.32%46 PS Ratio is 3.32 as of Aug. 05, 2026, which is 0% below its 10-year median of 3.33. GuruFocus rates NSE:INNOVACAP with a GF Score™ of 46/100. The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, Innova Captab ranks worse than 63.42% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Innova Captab's share price is ₹945.00.
Innova Captab's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹284.77. Hence, Innova Captab's PS Ratio for today is 3.32.
The historical rank and industry rank for Innova Captab's PS Ratio or its related term are showing as below:
NSE:INNOVACAP'
s PS Ratio Range Over the Past 10 Years
Min: 2.42 Med: 3.33 Max: 5.7
Current: 3.43
During the past 8 years, Innova Captab's highest PS Ratio was 5.70. The lowest was 2.42. And the median was 3.33.
NSE:INNOVACAP's PS Ratio is ranked worse than 63.42% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs NSE:INNOVACAP: 3.43
During the past 12 months, the average Revenue per Share Growth Rate of Innova Captab was 29.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 27.10% per year.
During the past 8 years, Innova Captab's highest 3-Year average Revenue per Share Growth Rate was 43.80% per year. The lowest was 15.60% per year. And the median was 19.60% per year.
Innova Captab (NSE:INNOVACAP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Innova Captab PS Ratio Related Terms
Innova Captab PS Ratio Historical Data
* Premium members only.
The historical data trend for Innova Captab's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's PS Ratio distribution charts can be found below:
* The bar in red indicates where Innova Captab's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Innova Captab's Share Price of today is ₹945.00. Innova Captab's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹284.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Innova Captab (NSE:INNOVACAP) has a PS Ratio of 3.32 as of Aug. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Innova Captab and its competitors. This is near median its historical median of 3.33. Over the past decade, Innova Captab's PS Ratio has ranged from 2.42 to 5.70. According to the industry distribution chart, Innova Captab ranks #605 out of 954 companies in the Drug Manufacturers industry, placing it in the top 63.4%.
Is Innova Captab's PS Ratio too high?
Innova Captab's current PS Ratio of 3.32 is near median its 10-year median of 3.33. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 5.70. The Drug Manufacturers industry median PS Ratio is 2.31. Innova Captab's value of 3.32 is 43.7% above this industry median. Based on the distribution chart, Innova Captab ranks #605 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Innova Captab has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #605 out of 954 companies for PS Ratio. This places Innova Captab in the lower half of its industry. The industry median PS Ratio is 2.31. Innova Captab's value of 3.32 is 43.7% above this benchmark. Historically, Innova Captab's own PS Ratio has ranged from 2.42 to 5.70 over the past decade. While the company's 10-year median is 3.33 vs. the industry median of 2.31, Innova Captab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current PS Ratio of 3.32 is 43.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current PS Ratio is 3.32, which is near median its own 10-year median of 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Innova Captab (NSE:INNOVACAP) has a current PS Ratio of 3.32. The current PS Ratio is 3.32, which is near median its 10-year median of 3.33 and 43.7% above the Drug Manufacturers industry median of 2.31. Innova Captab's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current PS Ratio is 3.32 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
46GF Score
Get the complete analysis for NSE:INNOVACAP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INNOVACAP has been successfully added to your 
